


wherein

R¹ is selected from



R² is hydrogen or lower alkoxy;


- 5 R³, R⁴, R⁵ and R⁶ are each independently selected from hydrogen, lower alkyl, halogenated lower alkyl, halogen or cycloalkyl; provided that R², R³, R⁴, R⁵ and R⁶ are not all hydrogen;

R⁷, R⁸ and R⁹ are each independently hydrogen, lower alkyl or lower alkoxy;

R¹⁰ is lower alkyl or halogenated lower alkyl;

- 10 and pharmaceutically acceptable salts thereof.

3. Compounds according to claims 1 or 2, wherein R¹ is



and R², R³, R⁴, R⁵ and R⁶ are as defined in claims 1 or 2.

4. Compounds according to claim 3, wherein R², R⁴, R⁵ and R⁶ are hydrogen and
15 R³ is lower alkyl, halogenated lower alkyl, halogen or cycloalkyl.


5. Compounds according to claim 4, wherein R², R⁴, R⁵ and R⁶ are hydrogen and R³ is lower alkyl, halogenated lower alkyl or halogen.

6. Compounds according to claim 3, wherein R², R⁴ and R⁵ are hydrogen and R³ and R⁶ are each independently lower alkyl, halogenated lower alkyl, halogen or cycloalkyl.

- 20 7. Compounds according to claim 3, wherein R², R⁴ and R⁵ are hydrogen and R³ and R⁶ are each independently lower alkyl or halogen.

8. Compounds according to claims 1 or 2, wherein R¹ is


- 48 -



and R^7 , R^8 and R^9 are as defined in claims 1 or 2.

9. Compounds according to claim 8, wherein R^7 and R^9 are hydrogen and R^8 is lower alkyl or lower alkoxy.

5 10. Compounds according to claims 1 or 2, wherein R^1 is



and R^{10} is as defined in claims 1 or 2.

11. Compounds according to any of claims 1 to 10, selected from the group consisting of:

10 *rac*-9,10-dimethoxy-3 β -*m*-tolyl-1,3,4,6,7,11 β -hexahydro-2H-pyrido[2,1-*a*]isoquinolin-2-ylamine hydrochloride,

rac-9,10-dimethoxy-3 β -*m*-tolyl-1,3,4,6,7,11 β -hexahydro-2H-pyrido[2,1-*a*]isoquinolin-2 β -ylamine,

15 9,10-dimethoxy-3(R)-*m*-tolyl-1,3,4,6,7,11b(R)-hexahydro-2H-pyrido[2,1-*a*]isoquinolin-2(S)-ylamine,

9,10-dimethoxy-3(S)-*m*-tolyl-1,3,4,6,7,11b(S)-hexahydro-2H-pyrido[2,1-*a*]isoquinolin-2(R)-ylamine,

rac-9,10-dimethoxy-3 β -*m*-tolyl-1,3,4,6,7,11 β -hexahydro-2H-pyrido[2,1-*a*]isoquinolin-2 α -ylamine,

20 9,10-dimethoxy-3(S)-*m*-tolyl-1,3,4,6,7,11b(S)-hexahydro-2H-pyrido[2,1-*a*]isoquinolin-2(S)-ylamine,

9,10-dimethoxy-3(R)-*m*-tolyl-1,3,4,6,7,11b(R)-hexahydro-2H-pyrido[2,1-*a*]isoquinolin-2(R)-ylamine,

25 *rac*-9,10-dimethoxy-3 β -(4-methyl-pyridin-2-yl)-1,3,4,6,7,11 β -hexahydro-2H-pyrido[2,1-*a*]isoquinolin-2 α -ylamine,